Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

RGIC19164, Qiu, EA2182, Colon/Rectal, Capecitabine, Fluorouracil, Mitomycin,

Research Question:
How well does lower-dose chemotherapy plus radiation therapy (chemoradiation) work in comparison to standard-dose chemoradiation in treating patients with early-stage anal cancer?

Basic Study Information

Purpose:
This phase II trial studies how well lower-dose chemotherapy plus radiation (chemoradiation) therapy works in comparison to standard-dose chemoradiation in treating patients with early-stage anal cancer. Drugs used in chemotherapy, such as mitomycin, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy with radiation therapy may kill more tumor cells. This study may help doctors find out if lower-dose chemoradiation is as effective and has fewer side effects than standard-dose chemoradiation, which is the usual approach for treatment of this cancer type.

Location: University of Rochester Medical Center
Study Reference #: RGIC19164

Lead Researcher (Principal Investigator)

Lead Researcher:  Haoming Qiu

Study Contact Information

Additional Study Details

Return to Search